[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-001", "question": "A 58-year-old woman with hypertrophic cardiomyopathy presents with recurrent syncope despite maximum-dose beta-blocker therapy. Echocardiography reveals a resting left ventricular outflow tract (LVOT) gradient of 85 mmHg, systolic anterior motion of the mitral valve, and septal thickness of 22 mm. Coronary angiography shows a large first septal perforator arising from the left anterior descending artery supplying the basal septum. She is referred for alcohol septal ablation. During the procedure, after balloon occlusion of the septal perforator and injection of echocardiographic contrast, opacification is noted in the papillary muscle region in addition to the target septal area. What is the most appropriate next step?", "options": ["Proceed with alcohol injection as planned given adequate septal opacification", "Abort the procedure and refer for surgical myectomy", "Advance the balloon more distally and reassess contrast distribution", "Reduce the planned alcohol volume by 50% and proceed", "Switch to a different septal perforator branch if available"], "answer": "C", "answer_index": 2, "explanation": "Papillary muscle opacification during alcohol septal ablation indicates that alcohol injection would cause papillary muscle necrosis, potentially resulting in severe mitral regurgitation. The appropriate step is to reposition the balloon more distally to exclude the branch supplying the papillary muscle. Proceeding with injection (A) or reducing volume (D) risks catastrophic mitral regurgitation. Aborting immediately (B) is premature before attempting repositioning. Switching perforators (E) may be considered only if repositioning fails and another suitable branch exists.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Symptomatic obstructive HCM with large basal septal perforator chosen for alcohol septal ablation; echo contrast after balloon occlusion shows opacification of both target septum and papillary muscle region, implying that the occluded territory perfuses papillary muscle. This raises risk of papillary muscle necrosis and severe MR if alcohol is injected.\\n\\nMost appropriate next step is to adjust technique to avoid papillary muscle involvement: reposition balloon more distally to exclude the branch to papillary muscle and then reassess contrast (Choice C). A (proceed anyway) and D (just reduce volume) are unsafe because any alcohol in that shared territory can injure the papillary muscle. B (abort and refer for myectomy) skips the standard remedial maneuver of repositioning. E (switch perforators) is a secondary option only if safe positioning in the main branch cannot be achieved.\\n\\nMain medical accuracy issues: None; the description of indications, technique, and complication risk for alcohol septal ablation is consistent with current practice.\\n\\nMinimal fix: Add a brief statement that repositioning the balloon more distally is technically feasible in this artery segment to further support C as the best next step.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Symptomatic obstructive HCM with large basal septal perforator chosen for alcohol septal ablation; echo contrast after balloon occlusion shows opacification of both target septum and papillary muscle region, implying that the occluded territory perfuses papillary muscle. This raises risk of papillary muscle necrosis and severe MR if alcohol is injected.\n\nMost appropriate next step is to adjust technique to avoid papillary muscle involvement: reposition balloon more distally to exclude the branch to papillary muscle and then reassess contrast (Choice C). A (proceed anyway) and D (just reduce volume) are unsafe because any alcohol in that shared territory can injure the papillary muscle. B (abort and refer for myectomy) skips the standard remedial maneuver of repositioning. E (switch perforators) is a secondary option only if safe positioning in the main branch cannot be achieved.\n\nMain medical accuracy issues: None; the description of indications, technique, and complication risk for alcohol septal ablation is consistent with current practice.\n\nMinimal fix: Add a brief statement that repositioning the balloon more distally is technically feasible in this artery segment to further support C as the best next step.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-002", "question": "A 34-year-old man presents with progressive gait instability and cognitive decline over 18 months. Examination reveals vertical supranuclear gaze palsy, axial rigidity greater than limb rigidity, early postural instability with falls, and frontal release signs. Brain MRI shows midbrain atrophy with the 'hummingbird sign.' Genetic testing reveals a heterozygous mutation in the MAPT gene. His father died at age 45 with a similar presentation. Which tau isoform predominates in the neuropathological inclusions of this patient's condition?", "options": ["3-repeat tau (3R) exclusively", "4-repeat tau (4R) exclusively", "Mixed 3R and 4R tau in equal proportions", "Hyperphosphorylated tau without repeat domain specificity", "Truncated tau lacking the microtubule-binding domain"], "answer": "B", "answer_index": 1, "explanation": "This presentation describes progressive supranuclear palsy (PSP) phenotype associated with MAPT mutation. PSP is a 4-repeat (4R) tauopathy, with tau inclusions composed predominantly of 4R tau isoforms. Pick disease is characterized by 3R tau (A), while Alzheimer disease shows mixed 3R/4R tau (C). The tau in PSP is hyperphosphorylated but specifically 4R predominant, making (D) incomplete. Truncated tau (E) is not characteristic of PSP pathology.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Young adult with progressive gait instability, vertical supranuclear gaze palsy, axial > limb rigidity, early falls, frontal release signs, MRI ‘hummingbird sign’ (midbrain atrophy), MAPT mutation, and autosomal dominant family history together define a PSP-spectrum tauopathy. PSP is classically a 4-repeat (4R) tauopathy, with inclusions composed predominantly of 4R tau isoforms. This directly supports option B.\\nMain logical issues: None. The stem clearly points to PSP; other answer choices are mapped to other known tauopathies (3R in Pick disease, mixed 3R/4R in Alzheimer disease). Option D is intentionally incomplete/overbroad compared with the specific 4R predominance in PSP, so it is appropriately incorrect. No internal contradictions or underspecification are present, and there is a single clearly best answer.\\nMain medical accuracy issues: None of significance. The characterization of PSP as a 4R tauopathy and the contrasts with Pick and Alzheimer disease are accurate and up-to-date.\\nMinimal fix: No essential fix needed; optionally specify “classic Richardson syndrome PSP phenotype” to further emphasize the diagnosis, though not required for clarity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Young adult with progressive gait instability, vertical supranuclear gaze palsy, axial > limb rigidity, early falls, frontal release signs, MRI ‘hummingbird sign’ (midbrain atrophy), MAPT mutation, and autosomal dominant family history together define a PSP-spectrum tauopathy. PSP is classically a 4-repeat (4R) tauopathy, with inclusions composed predominantly of 4R tau isoforms. This directly supports option B.\nMain logical issues: None. The stem clearly points to PSP; other answer choices are mapped to other known tauopathies (3R in Pick disease, mixed 3R/4R in Alzheimer disease). Option D is intentionally incomplete/overbroad compared with the specific 4R predominance in PSP, so it is appropriately incorrect. No internal contradictions or underspecification are present, and there is a single clearly best answer.\nMain medical accuracy issues: None of significance. The characterization of PSP as a 4R tauopathy and the contrasts with Pick and Alzheimer disease are accurate and up-to-date.\nMinimal fix: No essential fix needed; optionally specify “classic Richardson syndrome PSP phenotype” to further emphasize the diagnosis, though not required for clarity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-003", "question": "A 42-year-old woman with type 1 diabetes mellitus on insulin pump therapy presents with recurrent episodes of neuroglycopenia occurring 3-4 hours postprandially despite appropriate carbohydrate counting and bolus dosing. Continuous glucose monitoring shows rapid glucose drops from 180 mg/dL to 45 mg/dL within 90 minutes after meals. Gastric emptying study is normal. Anti-insulin antibodies are markedly elevated at 85% binding (normal <5%). Which mechanism best explains her hypoglycemic episodes?", "options": ["Antibody-mediated accelerated insulin clearance causing initial hyperglycemia followed by rebound hypoglycemia", "Antibody buffering of exogenous insulin with delayed release causing prolonged insulin action", "Cross-reactivity of anti-insulin antibodies with insulin receptors causing receptor activation", "Antibody-induced insulin resistance requiring higher doses with subsequent overdosing", "Complement-mediated destruction of pancreatic alpha cells reducing glucagon counterregulation"], "answer": "B", "answer_index": 1, "explanation": "Insulin autoimmune syndrome (IAS) or exogenous insulin antibody syndrome involves high-affinity anti-insulin antibodies that bind circulating insulin, creating a 'buffer' reservoir. This causes initial postprandial hyperglycemia (insulin bound and inactive), followed by delayed hypoglycemia when insulin dissociates from antibodies hours later. This explains the pattern of post-meal hyperglycemia followed by delayed severe hypoglycemia. Accelerated clearance (A) would cause persistent hyperglycemia. Receptor cross-reactivity (C) and alpha cell destruction (E) are not mechanisms of anti-insulin antibodies.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Type 1 diabetic on exogenous insulin pump; recurrent *delayed* postprandial neuroglycopenia 3–4 hours after meals; CGM shows initial high (180 mg/dL) then rapid fall to 45 mg/dL about 90 minutes post-meal; normal gastric emptying; *markedly elevated anti‑insulin antibodies* (85% binding). These strongly suggest an insulin antibody–mediated “buffering” phenomenon (insulin autoimmune/exogenous insulin antibody syndrome) with delayed release of bound insulin and late hypoglycemia.\\nOption B correctly describes antibody buffering of exogenous insulin with delayed release and prolonged action, matching classic pathophysiology and the provided rationale. Option A (accelerated clearance) would cause hyperglycemia, not delayed hypoglycemia. C (receptor activation) and D (insulin resistance/overdosing) do not fit the described timing pattern or documented high antibody binding acting as a reservoir. E (alpha cell destruction) is not a known effect of anti‑insulin antibodies and would not explain initial hyperglycemia.\\nNo major logical or medical inaccuracies are evident; the question is specific and sufficiently detailed to support a single best answer.\\nMinimal fix: Explicitly name this as exogenous insulin antibody syndrome in the explanation, but the item is already unambiguous and accurate without changes.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Type 1 diabetic on exogenous insulin pump; recurrent *delayed* postprandial neuroglycopenia 3–4 hours after meals; CGM shows initial high (180 mg/dL) then rapid fall to 45 mg/dL about 90 minutes post-meal; normal gastric emptying; *markedly elevated anti‑insulin antibodies* (85% binding). These strongly suggest an insulin antibody–mediated “buffering” phenomenon (insulin autoimmune/exogenous insulin antibody syndrome) with delayed release of bound insulin and late hypoglycemia.\nOption B correctly describes antibody buffering of exogenous insulin with delayed release and prolonged action, matching classic pathophysiology and the provided rationale. Option A (accelerated clearance) would cause hyperglycemia, not delayed hypoglycemia. C (receptor activation) and D (insulin resistance/overdosing) do not fit the described timing pattern or documented high antibody binding acting as a reservoir. E (alpha cell destruction) is not a known effect of anti‑insulin antibodies and would not explain initial hyperglycemia.\nNo major logical or medical inaccuracies are evident; the question is specific and sufficiently detailed to support a single best answer.\nMinimal fix: Explicitly name this as exogenous insulin antibody syndrome in the explanation, but the item is already unambiguous and accurate without changes.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-004", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy-defibrillator (CRT-D) presents for device interrogation. He reports improved functional capacity since implantation 6 months ago. Interrogation reveals 94% biventricular pacing. However, the device electrograms show that during intrinsic AV conduction, the LV lead captures occurs 40 ms after RV lead capture, and during biventricular pacing, LV capture occurs 15 ms before RV capture. His current AV delay is programmed at 120 ms sensed/150 ms paced. What programming change would most likely optimize his cardiac resynchronization?", "options": ["Shorten the AV delay to 80 ms sensed/110 ms paced", "Lengthen the AV delay to 180 ms sensed/210 ms paced", "Program VV delay with RV preceding LV by 40 ms", "Program VV delay with LV preceding RV by 30 ms", "Enable automatic AV and VV optimization algorithm"], "answer": "A", "answer_index": 0, "explanation": "The electrogram findings indicate that intrinsic conduction results in significant LV delay (LV activates 40 ms after RV), consistent with left bundle branch block pattern. During BiV pacing, LV leads RV by only 15 ms, suggesting suboptimal resynchronization. The key issue is that with a 120 ms AV delay, there may be fusion with intrinsic conduction compromising true biventricular capture. Shortening the AV delay ensures complete ventricular capture by the device before intrinsic conduction, maximizing resynchronization benefit. Programming RV to precede LV (C) would worsen the native LBBB pattern. Lengthening AV delay (B) would increase fusion. While automatic algorithms (E) exist, the specific findings here indicate the need for shorter AV delay.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Ischemic cardiomyopathy with CRT-D, improved but still suboptimal resynchronization; device shows intrinsic activation with LV 40 ms after RV (LBBB-like); during BiV pacing LV precedes RV by only 15 ms; AV delay currently 120/150 ms; and BiV pacing percentage is 94% (not 100%), implying intermittent intrinsic fusion. The question asks how to optimize CRT programming.\\nShortening the AV delay (A) is appropriate to pre-empt intrinsic AV conduction and avoid fusion, increasing consistent BiV capture and permitting the programmed VV offset to dominate. Lengthening AV delay (B) would worsen fusion. RV pre-excitation (C) would mimic/worsen LBBB pattern. LV pre-excitation by 30 ms (D) might help VV timing but does not address fusion caused by excessive AV delay and is less directly supported by the provided data than correcting AV timing. Automatic algorithms (E) is plausible but the stem gives specific electrogram evidence pointing to fusion needing manual AV shortening as the targeted intervention.\\nMain medical accuracy issues: None significant; reasoning is consistent with CRT optimization principles.\\nMinimal fix: Explicitly state that intrinsic AV conduction frequently competes with paced beats (fusion beats noted), to more strongly justify AV delay shortening as the primary intervention.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Ischemic cardiomyopathy with CRT-D, improved but still suboptimal resynchronization; device shows intrinsic activation with LV 40 ms after RV (LBBB-like); during BiV pacing LV precedes RV by only 15 ms; AV delay currently 120/150 ms; and BiV pacing percentage is 94% (not 100%), implying intermittent intrinsic fusion. The question asks how to optimize CRT programming.\nShortening the AV delay (A) is appropriate to pre-empt intrinsic AV conduction and avoid fusion, increasing consistent BiV capture and permitting the programmed VV offset to dominate. Lengthening AV delay (B) would worsen fusion. RV pre-excitation (C) would mimic/worsen LBBB pattern. LV pre-excitation by 30 ms (D) might help VV timing but does not address fusion caused by excessive AV delay and is less directly supported by the provided data than correcting AV timing. Automatic algorithms (E) is plausible but the stem gives specific electrogram evidence pointing to fusion needing manual AV shortening as the targeted intervention.\nMain medical accuracy issues: None significant; reasoning is consistent with CRT optimization principles.\nMinimal fix: Explicitly state that intrinsic AV conduction frequently competes with paced beats (fusion beats noted), to more strongly justify AV delay shortening as the primary intervention.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-005", "question": "A 29-year-old woman presents with acute onset of right-sided weakness and aphasia. CT head is negative for hemorrhage. CT angiography reveals complete occlusion of the left middle cerebral artery M1 segment. CT perfusion shows a small core infarct (8 mL) with large penumbra (95 mL mismatch). Her NIHSS is 18. Time last known well is 2 hours ago. She has a history of antiphospholipid syndrome with prior deep vein thrombosis, currently on warfarin with INR of 3.2. What is the most appropriate acute intervention?", "options": ["Intravenous alteplase followed by mechanical thrombectomy", "Mechanical thrombectomy alone without intravenous thrombolysis", "Intravenous alteplase alone with close monitoring", "Administer 4-factor prothrombin complex concentrate then IV alteplase and thrombectomy", "Anticoagulation reversal with idarucizumab followed by mechanical thrombectomy"], "answer": "B", "answer_index": 1, "explanation": "This patient has a large vessel occlusion with favorable perfusion imaging (small core, large penumbra) within the thrombectomy window. However, her INR of 3.2 is a contraindication to IV alteplase (INR >1.7 is exclusion criterion). Mechanical thrombectomy is not contraindicated by anticoagulation status and should be performed emergently. IV alteplase (A, C) is contraindicated with therapeutic anticoagulation. PCC reversal followed by alteplase (D) delays definitive treatment and alteplase remains relatively contraindicated even after reversal. Idarucizumab (E) reverses dabigatran, not warfarin.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 29-year-old with acute disabling ischemic stroke (NIHSS 18), CT showing no hemorrhage, CTA with left M1 large vessel occlusion, CT perfusion with small core (8 mL) and large penumbra, onset 2 hours ago (within both IVT and MT windows), on warfarin with INR 3.2. Warfarin with INR >1.7 is an absolute contraindication to IV alteplase but does not preclude mechanical thrombectomy.\\n\\nOption B (mechanical thrombectomy alone) is therefore the single best evidence-based intervention. Options A and C inappropriately include alteplase despite INR 3.2. Option D proposes warfarin reversal with PCC solely to enable alteplase, which is not guideline-supported, would delay reperfusion, and does not clearly make alteplase safe. Option E uses idarucizumab, which is specific for dabigatran, not warfarin, and is inappropriate here.\\n\\nMain logical issue(s): None; stem is coherent, imaging and lab data are sufficient to guide a unique best answer.\\n\\nMain medical accuracy issue(s): None; reasoning aligns with current acute ischemic stroke and thrombectomy guidelines.\\n\\nMinimal fix: None required; at most, specify that endovascular-capable center resources are immediately available to remove any residual ambiguity about feasibility of thrombectomy.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 29-year-old with acute disabling ischemic stroke (NIHSS 18), CT showing no hemorrhage, CTA with left M1 large vessel occlusion, CT perfusion with small core (8 mL) and large penumbra, onset 2 hours ago (within both IVT and MT windows), on warfarin with INR 3.2. Warfarin with INR >1.7 is an absolute contraindication to IV alteplase but does not preclude mechanical thrombectomy.\n\nOption B (mechanical thrombectomy alone) is therefore the single best evidence-based intervention. Options A and C inappropriately include alteplase despite INR 3.2. Option D proposes warfarin reversal with PCC solely to enable alteplase, which is not guideline-supported, would delay reperfusion, and does not clearly make alteplase safe. Option E uses idarucizumab, which is specific for dabigatran, not warfarin, and is inappropriate here.\n\nMain logical issue(s): None; stem is coherent, imaging and lab data are sufficient to guide a unique best answer.\n\nMain medical accuracy issue(s): None; reasoning aligns with current acute ischemic stroke and thrombectomy guidelines.\n\nMinimal fix: None required; at most, specify that endovascular-capable center resources are immediately available to remove any residual ambiguity about feasibility of thrombectomy.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-006", "question": "A 55-year-old man with severe persistent asthma on high-dose inhaled corticosteroids, long-acting beta-agonist, long-acting muscarinic antagonist, and monthly omalizumab presents with continued poor control. Spirometry shows FEV1 45% predicted with 15% bronchodilator response. Laboratory studies reveal blood eosinophils 450 cells/μL, total IgE 850 IU/mL, and FeNO 55 ppb. Sputum analysis shows 8% eosinophils. Despite confirmed adherence and proper inhaler technique, he has had 4 exacerbations requiring systemic corticosteroids in the past year. Which biologic switch would most likely provide additional benefit?", "options": ["Dupilumab targeting IL-4 receptor alpha", "Benralizumab targeting IL-5 receptor alpha", "Mepolizumab targeting IL-5", "Tezepelumab targeting thymic stromal lymphopoietin", "Continue omalizumab with addition of low-dose oral corticosteroids"], "answer": "D", "answer_index": 3, "explanation": "This patient has severe eosinophilic asthma failing omalizumab (anti-IgE) therapy despite elevated biomarkers (eosinophils, FeNO). Tezepelumab targets TSLP, an epithelial cytokine upstream of multiple inflammatory pathways (Th2, ILC2), and has demonstrated efficacy regardless of baseline eosinophil count or IgE levels, including in patients who failed other biologics. While anti-IL-5/IL-5R agents (B, C) and dupilumab (A) target eosinophilic inflammation, tezepelumab's upstream mechanism may provide benefit when anti-IgE therapy has failed despite persistent type 2 inflammation. Adding oral corticosteroids (E) increases adverse effects without addressing the underlying inflammatory pathway.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Severe persistent asthma on maximal inhaled therapy plus omalizumab; persistent poor control with 4 steroid-requiring exacerbations; FEV1 45% predicted; high type 2 biomarkers (blood eosinophils 450/µL, FeNO 55 ppb, sputum eos 8%, IgE 850) despite adherence and proper technique; question asks which biologic switch would most likely provide additional benefit.\\nThe most appropriate next biologic is tezepelumab, which targets TSLP upstream of IL-4/5/13 pathways and has evidence of benefit across biomarker ranges, including in patients with prior biologic failure. Other options (dupilumab, benralizumab, mepolizumab) are also reasonable T2-directed choices but are mechanistically more downstream and not clearly superior after anti-IgE failure given the stem’s emphasis on persistent T2 inflammation and the explanation’s teaching point about upstream blockade. Option E (adding chronic oral steroids) is disfavored due to toxicity and lack of targeted mechanism.\\nMain medical issues: Slightly debatable hierarchy among biologics, but within board-style “single best” framing, tezepelumab is defensible as best given current evidence. Minimal fix: Explicitly state that the clinician wishes to switch to a biologic with efficacy after prior biologic failure and across biomarker levels to reinforce tezepelumab as uniquely best.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Severe persistent asthma on maximal inhaled therapy plus omalizumab; persistent poor control with 4 steroid-requiring exacerbations; FEV1 45% predicted; high type 2 biomarkers (blood eosinophils 450/µL, FeNO 55 ppb, sputum eos 8%, IgE 850) despite adherence and proper technique; question asks which biologic switch would most likely provide additional benefit.\nThe most appropriate next biologic is tezepelumab, which targets TSLP upstream of IL-4/5/13 pathways and has evidence of benefit across biomarker ranges, including in patients with prior biologic failure. Other options (dupilumab, benralizumab, mepolizumab) are also reasonable T2-directed choices but are mechanistically more downstream and not clearly superior after anti-IgE failure given the stem’s emphasis on persistent T2 inflammation and the explanation’s teaching point about upstream blockade. Option E (adding chronic oral steroids) is disfavored due to toxicity and lack of targeted mechanism.\nMain medical issues: Slightly debatable hierarchy among biologics, but within board-style “single best” framing, tezepelumab is defensible as best given current evidence. Minimal fix: Explicitly state that the clinician wishes to switch to a biologic with efficacy after prior biologic failure and across biomarker levels to reinforce tezepelumab as uniquely best.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-007", "question": "A 48-year-old woman is brought to the emergency department after being found unresponsive at home. She has a history of depression. On examination, she is comatose with pinpoint pupils, respiratory rate of 6/min, temperature 35.8°C, and blood pressure 90/60 mmHg. ECG shows QRS duration of 145 ms with a terminal R wave in aVR of 4 mm. After securing the airway and administering naloxone without response, what is the most appropriate next intervention?", "options": ["Intravenous flumazenil 0.2 mg", "Intravenous sodium bicarbonate bolus targeting serum pH 7.50-7.55", "Intravenous lipid emulsion 20% bolus", "Intravenous glucagon 5 mg bolus", "Emergent hemodialysis"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation (coma, miosis, respiratory depression, hypotension) with ECG findings of QRS widening >100 ms and terminal R wave in aVR >3 mm is classic for tricyclic antidepressant (TCA) toxicity. The sodium channel blockade causing cardiac toxicity is treated with sodium bicarbonate, which increases extracellular sodium (overcoming channel blockade) and alkalinizes serum (increasing protein binding of TCA). Target pH is 7.50-7.55. Flumazenil (A) is contraindicated as it may precipitate seizures in TCA overdose. Lipid emulsion (C) is second-line. Glucagon (D) is for beta-blocker toxicity. Hemodialysis (E) is ineffective for TCAs due to high protein binding and large volume of distribution.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Middle-aged woman with history of depression; coma, pinpoint pupils, severe respiratory depression and hypotension; ECG with markedly widened QRS (145 ms) and terminal R in aVR of 4 mm; no response to naloxone. These are characteristic of tricyclic antidepressant (TCA) overdose with sodium-channel blockade cardiotoxicity. Standard management after airway/ventilation is IV sodium bicarbonate bolus with goal serum pH 7.50–7.55 to narrow the QRS and treat ventricular arrhythmia risk.\\nOption appraisal: B correctly targets TCA Na-channel blockade. A (flumazenil) is inappropriate and potentially dangerous in TCA overdosage because of seizure risk. C (lipid emulsion) is considered second-line/adjunctive when bicarbonate fails, not the most appropriate next step. D (glucagon) is for beta-blocker toxicity, not supported by the ECG findings. E (hemodialysis) is ineffective in TCA poisoning due to high protein binding and volume of distribution.\\nMain medical accuracy issues: None significant; description of ECG criteria, mechanism, and treatment is accurate and aligned with current toxicology guidance.\\nMinimal fix: Consider explicitly stating recent ingestion of a tricyclic antidepressant in the stem to make the diagnosis even more straightforward, though it is already adequately implied by the ECG findings and history of depression.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Middle-aged woman with history of depression; coma, pinpoint pupils, severe respiratory depression and hypotension; ECG with markedly widened QRS (145 ms) and terminal R in aVR of 4 mm; no response to naloxone. These are characteristic of tricyclic antidepressant (TCA) overdose with sodium-channel blockade cardiotoxicity. Standard management after airway/ventilation is IV sodium bicarbonate bolus with goal serum pH 7.50–7.55 to narrow the QRS and treat ventricular arrhythmia risk.\nOption appraisal: B correctly targets TCA Na-channel blockade. A (flumazenil) is inappropriate and potentially dangerous in TCA overdosage because of seizure risk. C (lipid emulsion) is considered second-line/adjunctive when bicarbonate fails, not the most appropriate next step. D (glucagon) is for beta-blocker toxicity, not supported by the ECG findings. E (hemodialysis) is ineffective in TCA poisoning due to high protein binding and volume of distribution.\nMain medical accuracy issues: None significant; description of ECG criteria, mechanism, and treatment is accurate and aligned with current toxicology guidance.\nMinimal fix: Consider explicitly stating recent ingestion of a tricyclic antidepressant in the stem to make the diagnosis even more straightforward, though it is already adequately implied by the ECG findings and history of depression.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-008", "question": "A 62-year-old man with longstanding type 2 diabetes presents with a 6-month history of burning pain and numbness in his feet, now extending to mid-calf. Examination reveals absent ankle reflexes, reduced pinprick and vibration sense to the knees bilaterally, and mild weakness of toe extension. Nerve conduction studies show absent sural sensory responses, reduced peroneal motor amplitudes with mildly slowed conduction velocities, and prolonged F-wave latencies. Hemoglobin A1c is 7.2%. He is started on duloxetine with minimal improvement after 8 weeks. Gabapentin is added and titrated to 1800 mg daily with partial response. Which additional intervention has the strongest evidence for further symptomatic improvement?", "options": ["Alpha-lipoic acid 600 mg IV daily for 3 weeks", "Topical capsaicin 8% patch application to affected areas", "Spinal cord stimulation trial", "Transcutaneous electrical nerve stimulation (TENS)", "Acupuncture twice weekly for 12 weeks"], "answer": "C", "answer_index": 2, "explanation": "This patient has painful diabetic peripheral neuropathy refractory to first-line (duloxetine) and second-line (gabapentin) pharmacotherapy. Spinal cord stimulation (SCS) has Level 1 evidence from randomized controlled trials (SENZA-PDN, others) demonstrating significant pain reduction in refractory painful diabetic neuropathy, with FDA approval for this indication. Alpha-lipoic acid (A) has modest evidence primarily from European studies. High-concentration capsaicin (B) provides temporary relief but evidence in diabetic neuropathy is limited. TENS (D) and acupuncture (E) have weaker evidence compared to SCS for refractory cases.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Longstanding type 2 diabetes; length-dependent sensory > motor neuropathy with typical NCS findings; painful diabetic peripheral neuropathy; inadequate response to duloxetine then adequately titrated gabapentin (refractory to standard pharmacotherapy). The question asks which additional intervention has the strongest evidence for further symptomatic improvement.\\nSpinal cord stimulation (SCS) has high-level evidence (e.g., SENZA-PDN) showing significant pain reduction and functional benefit in painful diabetic neuropathy refractory to medications, with regulatory approval for this indication. Among listed options, SCS clearly has the strongest contemporary evidence base and is appropriate for refractory disease.\\nOther options: Alpha-lipoic acid has modest and mainly European data with smaller effect sizes; high-dose capsaicin patch is FDA approved for neuropathic pain but evidence in diabetic neuropathy is less robust than SCS for refractory cases; TENS and acupuncture have weaker, less consistent trial data and are usually adjuncts, not the strongest-evidence option in this setting.\\nMain medical issue: None substantive; sequencing after failure of two agents is clinically plausible. Minimal fix: Specify “refractory painful diabetic peripheral neuropathy despite adequate trials of first- and second-line pharmacologic therapy” in stem to stress refractoriness.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Longstanding type 2 diabetes; length-dependent sensory > motor neuropathy with typical NCS findings; painful diabetic peripheral neuropathy; inadequate response to duloxetine then adequately titrated gabapentin (refractory to standard pharmacotherapy). The question asks which additional intervention has the strongest evidence for further symptomatic improvement.\nSpinal cord stimulation (SCS) has high-level evidence (e.g., SENZA-PDN) showing significant pain reduction and functional benefit in painful diabetic neuropathy refractory to medications, with regulatory approval for this indication. Among listed options, SCS clearly has the strongest contemporary evidence base and is appropriate for refractory disease.\nOther options: Alpha-lipoic acid has modest and mainly European data with smaller effect sizes; high-dose capsaicin patch is FDA approved for neuropathic pain but evidence in diabetic neuropathy is less robust than SCS for refractory cases; TENS and acupuncture have weaker, less consistent trial data and are usually adjuncts, not the strongest-evidence option in this setting.\nMain medical issue: None substantive; sequencing after failure of two agents is clinically plausible. Minimal fix: Specify “refractory painful diabetic peripheral neuropathy despite adequate trials of first- and second-line pharmacologic therapy” in stem to stress refractoriness.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-009", "question": "A 71-year-old man with COPD GOLD stage III is hospitalized for acute exacerbation. On day 3, despite antibiotics, systemic corticosteroids, and scheduled bronchodilators, he remains dyspneic with respiratory rate 28/min, accessory muscle use, and ABG showing pH 7.31, PaCO2 58 mmHg, PaO2 55 mmHg on 4L nasal cannula. He is alert and cooperative. Bilevel positive airway pressure (BiPAP) is initiated at IPAP 12/EPAP 5 cm H2O. After 2 hours, repeat ABG shows pH 7.29, PaCO2 62 mmHg. He remains tachypneic but is tolerating the mask. What is the most appropriate next step?", "options": ["Increase IPAP to 18 cm H2O and reassess in 1-2 hours", "Proceed with endotracheal intubation and mechanical ventilation", "Add heliox (helium-oxygen mixture) to the BiPAP circuit", "Switch to high-flow nasal cannula at 60 L/min", "Increase EPAP to 10 cm H2O while maintaining IPAP"], "answer": "A", "answer_index": 0, "explanation": "The patient has acute hypercapnic respiratory failure from COPD exacerbation with initial NIV settings that are inadequate (worsening hypercapnia). The driving pressure (IPAP-EPAP = 7 cm H2O) is insufficient for adequate ventilation. Increasing IPAP to 18 cm H2O (driving pressure 13 cm H2O) will augment tidal volume and improve CO2 clearance. Intubation (B) is premature as he is tolerating NIV and is not deteriorating clinically. Heliox (C) reduces airway resistance but doesn't address ventilation. HFNC (D) provides less ventilatory support than BiPAP for hypercapnic failure. Increasing EPAP alone (E) would reduce driving pressure further, worsening ventilation.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Elderly man with GOLD III COPD, acute hypercapnic respiratory failure (pH 7.31 → 7.29, PaCO2 58 → 62) on day 3 of exacerbation; already on appropriate medical therapy; started on BiPAP with relatively low driving pressure (IPAP 12, EPAP 5 → ΔP 7); after 2 hours, still tachypneic, hypercapnia slightly worse, but remains alert, cooperative, and tolerating mask.\\nThese findings indicate inadequate ventilatory support on NIV, not NIV failure. The most appropriate step is to increase inspiratory pressure to augment tidal volume and CO2 clearance (choice A). Intubation (B) is reserved for worsening mental status, intolerance, severe acidosis, or imminent arrest; not yet present. Heliox (C) may reduce work of breathing but does not directly correct inadequate ventilation and is not standard next step. HFNC (D) provides mainly oxygenation and modest washout of dead space, inferior to BiPAP for hypercapnic COPD. Increasing EPAP to 10 (E) would reduce driving pressure and likely worsen hypercapnia.\\nMain medical issues: None significant; management and rationale align with guideline-based NIV titration in COPD exacerbation.\\nMinimal fix: Option A could specify a target pH/PaCO2 or mention typical maximum IPAP range (e.g., 18–20 cm H2O) for clarity, but item is already unambiguous and accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Elderly man with GOLD III COPD, acute hypercapnic respiratory failure (pH 7.31 → 7.29, PaCO2 58 → 62) on day 3 of exacerbation; already on appropriate medical therapy; started on BiPAP with relatively low driving pressure (IPAP 12, EPAP 5 → ΔP 7); after 2 hours, still tachypneic, hypercapnia slightly worse, but remains alert, cooperative, and tolerating mask.\nThese findings indicate inadequate ventilatory support on NIV, not NIV failure. The most appropriate step is to increase inspiratory pressure to augment tidal volume and CO2 clearance (choice A). Intubation (B) is reserved for worsening mental status, intolerance, severe acidosis, or imminent arrest; not yet present. Heliox (C) may reduce work of breathing but does not directly correct inadequate ventilation and is not standard next step. HFNC (D) provides mainly oxygenation and modest washout of dead space, inferior to BiPAP for hypercapnic COPD. Increasing EPAP to 10 (E) would reduce driving pressure and likely worsen hypercapnia.\nMain medical issues: None significant; management and rationale align with guideline-based NIV titration in COPD exacerbation.\nMinimal fix: Option A could specify a target pH/PaCO2 or mention typical maximum IPAP range (e.g., 18–20 cm H2O) for clarity, but item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-010", "question": "A 38-year-old woman presents with palpitations and near-syncope. ECG shows a regular wide complex tachycardia at 220 bpm with RBBB morphology, northwest axis, and AV dissociation. She is hemodynamically stable with blood pressure 105/70 mmHg. Adenosine 12 mg IV is administered without effect. Procainamide infusion is started, and after 8 minutes (750 mg administered), the rhythm converts to sinus. Post-conversion ECG reveals sinus rhythm with a short PR interval (100 ms), delta waves, and QRS duration of 140 ms with positive delta wave in V1. Which electrophysiologic finding would most strongly support proceeding with catheter ablation rather than medical management?", "options": ["Accessory pathway effective refractory period of 270 ms", "Inducible orthodromic atrioventricular reentrant tachycardia", "Accessory pathway located in the left lateral position", "Shortest pre-excited RR interval during induced atrial fibrillation of 220 ms", "Decremental conduction properties of the accessory pathway"], "answer": "D", "answer_index": 3, "explanation": "This patient has Wolff-Parkinson-White syndrome with documented antidromic AVRT (wide complex tachycardia with AV dissociation, RBBB morphology suggesting left-sided pathway). The most important risk stratification parameter is the shortest pre-excited RR interval (SPERRI) during atrial fibrillation, which reflects the accessory pathway's ability to conduct rapid atrial rates to the ventricle. SPERRI ≤250 ms indicates high-risk pathway capable of conducting AF at rates that could degenerate to ventricular fibrillation, strongly favoring ablation. Accessory pathway ERP (A) is less predictive than SPERRI. Inducible orthodromic AVRT (B) and pathway location (C) don't indicate sudden death risk. Decremental properties (E) actually suggest lower risk.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Post-conversion ECG with short PR, delta wave, wide QRS confirms WPW. The initial arrhythmia is a wide complex tachycardia consistent with AVRT in the setting of an accessory pathway. The question asks which EP-lab finding most strongly supports proceeding with ablation rather than chronic medical therapy. Among EP risk-stratification metrics, the shortest pre-excited RR interval (SPERRI) during induced AF is the key predictor of life‑threatening conduction over the pathway. A SPERRI ≤250 ms is considered high risk and is a strong indication for ablation.\\nOption analysis: D (SPERRI 220 ms) is high-risk and the best indication for ablation. A (ERP 270 ms) is relatively long and less predictive of sudden death than SPERRI. B (inducible orthodromic AVRT) denotes symptomatic tachycardia but not necessarily high sudden death risk; ablation is reasonable but not as strongly compelled by risk. C (left lateral location) doesn’t determine risk. E (decremental conduction) is associated with lower risk.\\nMain medical issues: Minor—initial rhythm description mixes features (AV dissociation) atypical for classic AVRT, but does not affect the teaching point.\\nMinimal fix: Clarify initial tachycardia as “pre-excited atrial arrhythmia/AVRT compatible with WPW” without implying AV dissociation, or adjust description to match typical antidromic AVRT findings.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Post-conversion ECG with short PR, delta wave, wide QRS confirms WPW. The initial arrhythmia is a wide complex tachycardia consistent with AVRT in the setting of an accessory pathway. The question asks which EP-lab finding most strongly supports proceeding with ablation rather than chronic medical therapy. Among EP risk-stratification metrics, the shortest pre-excited RR interval (SPERRI) during induced AF is the key predictor of life‑threatening conduction over the pathway. A SPERRI ≤250 ms is considered high risk and is a strong indication for ablation.\nOption analysis: D (SPERRI 220 ms) is high-risk and the best indication for ablation. A (ERP 270 ms) is relatively long and less predictive of sudden death than SPERRI. B (inducible orthodromic AVRT) denotes symptomatic tachycardia but not necessarily high sudden death risk; ablation is reasonable but not as strongly compelled by risk. C (left lateral location) doesn’t determine risk. E (decremental conduction) is associated with lower risk.\nMain medical issues: Minor—initial rhythm description mixes features (AV dissociation) atypical for classic AVRT, but does not affect the teaching point.\nMinimal fix: Clarify initial tachycardia as “pre-excited atrial arrhythmia/AVRT compatible with WPW” without implying AV dissociation, or adjust description to match typical antidromic AVRT findings.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]